Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT.
Sackley CM, Rick C, Brady MC, Burton C, Jowett S, Patel S, Woolley R, Masterson-Algar P, Nicoll A, Smith CH, Abdali Z, Ives N, Beaton G, Dickson S, Ottridge R, Nankervis H, Clarke CE; PD COMM Collaborative Group. Sackley CM, et al. Among authors: rick c. Health Technol Assess. 2024 Oct;28(58):1-141. doi: 10.3310/ADWP8001. Health Technol Assess. 2024. PMID: 39364774 Free PMC article. Clinical Trial.
A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
Sackley CM, Rick C, Au P, Brady MC, Beaton G, Burton C, Caulfield M, Dickson S, Dowling F, Hughes M, Ives N, Jowett S, Masterson-Algar P, Nicoll A, Patel S, Smith CH, Woolley R, Clarke CE; PD COMM Collaborative Group. Sackley CM, et al. Among authors: rick c. Trials. 2020 May 27;21(1):436. doi: 10.1186/s13063-020-04354-7. Trials. 2020. PMID: 32460885 Free PMC article.
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.
Scobie S, Jowett S, Lambe T, Patel S, Woolley R, Ives N, Rick C, Smith C, Brady MC, Clarke C, Sackley C. Scobie S, et al. Among authors: rick c. Pilot Feasibility Stud. 2021 Aug 9;7(1):154. doi: 10.1186/s40814-021-00888-y. Pilot Feasibility Stud. 2021. PMID: 34372913 Free PMC article.
Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.
Sackley CM, Rick C, Brady MC, Woolley R, Burton C, Patel S, Masterson-Algar P, Nicoll A, Smith CH, Jowett S, Ives N, Beaton G, Dickson S, Ottridge R, Sharp L, Nankervis H, Clarke CE; PD COMM collaborative group. Sackley CM, et al. Among authors: rick c. BMJ. 2024 Jul 10;386:e078341. doi: 10.1136/bmj-2023-078341. BMJ. 2024. PMID: 38986549 Free PMC article. Clinical Trial.
Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial.
Sackley CM, Smith CH, Rick C, Brady MC, Ives N, Patel R, Roberts H, Dowling F, Jowett S, Wheatley K, Patel S, Kelly D, Sands G, Clarke C. Sackley CM, et al. Among authors: rick c. Trials. 2014 Jun 7;15:213. doi: 10.1186/1745-6215-15-213. Trials. 2014. PMID: 24908096 Free PMC article. Clinical Trial.
Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol.
Ottridge R, Mollan SP, Botfield H, Frew E, Ives NJ, Matthews T, Mitchell J, Rick C, Singhal R, Woolley R, Sinclair AJ. Ottridge R, et al. Among authors: rick c. BMJ Open. 2017 Sep 27;7(9):e017426. doi: 10.1136/bmjopen-2017-017426. BMJ Open. 2017. PMID: 28963303 Free PMC article. Clinical Trial.
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. Among authors: rick c. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.
116 results